Stock PD2 PATTERSON COMPANIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Patterson Companies, Inc. Berne S.E.

Equities

PD2

US7033951036

Medical Equipment, Supplies & Distribution

Delayed Berne S.E.
Other stock markets
 		5-day change 1st Jan Change
- CHF -.--% Intraday chart for Patterson Companies, Inc. -.--% -.--%
20/06 Morgan Stanley Adjusts Price Target on Patterson Companies to $28 From $30, Maintains Equalweight Rating MT
20/06 JPMorgan Adjusts Price Target on Patterson Companies to $29 From $30, Maintains Neutral Rating MT

Valuation

Fiscal Period: April 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 1,511 3,131 3,084 2,649 2,309 2,122 - -
Enterprise Value (EV) 1 2,021 3,629 3,459 3,117 2,957 2,549 2,487 2,406
P/E ratio -2.56 x 20.4 x 15.3 x 12.8 x 13 x 11.7 x 10.9 x 9.73 x
Yield 6.5% 3.16% 3.29% 3.84% 4.04% 4.41% 4.46% 3.68%
Capitalization / Revenue 0.28 x 0.53 x 0.47 x 0.41 x 0.35 x 0.32 x 0.31 x 0.29 x
EV / Revenue 0.37 x 0.61 x 0.53 x 0.48 x 0.45 x 0.38 x 0.36 x 0.33 x
EV / EBITDA 7.17 x 12.5 x 10.5 x 8.67 x 7.54 x 7.02 x 6.42 x 5.99 x
EV / FCF -7.08 x -4.8 x -3.39 x -3.81 x -3.45 x 11.6 x 10.3 x 9.22 x
FCF Yield -14.1% -20.8% -29.5% -26.3% -29% 8.59% 9.73% 10.8%
Price to Book 1.8 x 3.3 x 2.98 x - - 2.08 x 1.9 x 1.65 x
Nbr of stocks (in thousands) 94,376 95,188 97,622 97,708 89,592 87,760 - -
Reference price 2 16.01 32.89 31.59 27.11 25.77 24.18 24.18 24.18
Announcement Date 24/06/20 23/06/21 29/06/22 21/06/23 18/06/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: April 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 5,490 5,912 6,499 6,471 6,568 6,729 6,953 7,234
EBITDA 1 281.8 290.6 328.4 359.7 392.1 363.1 387 401.8
EBIT 1 236.7 248.7 284.3 313.9 303.9 312 333.6 352.7
Operating Margin 4.31% 4.21% 4.37% 4.85% 4.63% 4.64% 4.8% 4.88%
Earnings before Tax (EBT) 1 -590.4 199.9 266.3 270.2 243.1 242.1 276 -
Net income 1 -588.4 156 203.2 207.6 185.9 186.2 198.5 213.1
Net margin -10.72% 2.64% 3.13% 3.21% 2.83% 2.77% 2.86% 2.95%
EPS 2 -6.250 1.610 2.060 2.120 1.980 2.058 2.226 2.484
Free Cash Flow 1 -285.4 -756.3 -1,019 -819.1 -857 219 242 261
FCF margin -5.2% -12.79% -15.68% -12.66% -13.05% 3.25% 3.48% 3.61%
FCF Conversion (EBITDA) - - - - - 60.32% 62.53% 64.96%
FCF Conversion (Net income) - - - - - 117.6% 121.89% 122.49%
Dividend per Share 2 1.040 1.040 1.040 1.040 1.040 1.067 1.079 0.8898
Announcement Date 24/06/20 23/06/21 29/06/22 21/06/23 18/06/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: April 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1
Net sales 1 1,597 1,639 1,523 1,626 1,601 1,721 1,577 1,653 1,616 1,723 1,591 1,688 1,659 1,779 1,647
EBITDA 1 81.26 93.42 55.02 81.01 97.13 126.5 59.26 91.12 98.53 126.8 55.08 82.61 93.96 122.6 60.68
EBIT 1 70.08 82.24 44.2 69.42 85.4 114.9 47.85 69.32 76.17 103.8 44.7 69.91 81.33 111 52.83
Operating Margin 4.39% 5.02% 2.9% 4.27% 5.33% 6.67% 3.03% 4.19% 4.71% 6.03% 2.81% 4.14% 4.9% 6.24% 3.21%
Earnings before Tax (EBT) 1 75.23 82.35 31.06 70.75 69.29 99.06 40.61 53.36 61.94 87.14 28.3 54.4 67.8 91.6 35.3
Net income 1 57.01 63.88 24.59 54.07 53.93 74.96 31.23 39.96 47.7 67.04 22.09 41.18 50.54 71.4 26.45
Net margin 3.57% 3.9% 1.61% 3.33% 3.37% 4.36% 1.98% 2.42% 2.95% 3.89% 1.39% 2.44% 3.05% 4.01% 1.61%
EPS 2 0.5800 0.6500 0.2500 0.5500 0.5500 0.7700 0.3200 0.4200 0.5200 0.7400 0.2616 0.4707 0.5486 0.8029 0.3477
Dividend per Share 2 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600 0.2600
Announcement Date 02/03/22 29/06/22 01/09/22 01/12/22 02/03/23 21/06/23 30/08/23 29/11/23 28/02/24 18/06/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: April 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 510 498 376 468 648 427 364 284
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.809 x 1.714 x 1.143 x 1.302 x 1.654 x 1.176 x 0.9418 x 0.7072 x
Free Cash Flow 1 -285 -756 -1,019 -819 -857 219 242 261
ROE (net income / shareholders' equity) 12.7% 17.4% 20.2% 21.9% - 20.7% 21.2% 20.5%
ROA (Net income/ Total Assets) 4.93% 5.71% 8.15% 8.41% 7.45% 7.3% 7.67% 7.83%
Assets 1 -11,930 2,733 2,495 2,467 2,495 2,553 2,588 2,722
Book Value Per Share 2 8.880 9.960 10.60 - - 11.60 12.80 14.70
Cash Flow per Share 2 -2.590 -7.560 -9.960 -7.720 -8.430 2.920 3.020 -
Capex 1 41.8 25.8 38.3 64.2 67.6 60.3 61.3 62.3
Capex / Sales 0.76% 0.44% 0.59% 0.99% 1.03% 0.9% 0.88% 0.86%
Announcement Date 24/06/20 23/06/21 29/06/22 21/06/23 18/06/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Patterson Companies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
24.18 USD
Average target price
28.64 USD
Spread / Average Target
+18.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.16% 184B
MEDTRONIC PLC Stock Medtronic plc
-2.39% 103B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.08% 67.59B
CENCORA, INC. Stock Cencora, Inc.
+16.04% 46.93B
DEXCOM, INC. Stock DexCom, Inc.
-11.10% 43.87B
HOYA CORPORATION Stock Hoya Corporation
+8.28% 41.2B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+17.63% 30.47B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.10% 23.57B
TERUMO CORPORATION Stock Terumo Corporation
+13.59% 24.16B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. PDCO Stock
  4. PD2 Stock
  5. Financials Patterson Companies, Inc.